Courtesy of Gilead Sciences
Courtesy of Gilead Sciences

The maker of remdesivir, a drug known to reduce the recovery time of acutely ill coronavirus patients, said Monday it will charge $2,340 for a normal treatment course for people who participate in government health programs in the U.S. and for governments of other developing countries.

Gilead Sciences announced it will charge $390 per vial, with a typical five-day course consisting of six vials.

Patients who have private insurance will be billed $3,120, or $520 a vial.

“We’re in [uncharted] territory with pricing a new medicine, a novel medicine, in a pandemic,” said Gilead CEO Daniel O’Day.

Did you like this story?
Would you like to receive articles like this in your inbox? Free!

WI Guest Author

This correspondent is a guest contributor to The Washington Informer.

Leave a comment

Your email address will not be published. Required fields are marked *